Eric Venker, President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 1,330,318 shares at $16.34 ($21.6M) on 2025-10-06, disclosed to the SEC on 2025-10-08.
Scheduled sale ($21.6M) by President & Immunovant CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.34 | 171,396 | $2.8M | 13.0% |
| 2 | $16.34 | 171,396 | $2.8M | 13.0% |
| 3 | $16.15 | 355,161 | $5.7M | 26.6% |
| 4 | $16.15 | 355,161 | $5.7M | 26.6% |
| 5 | $16.20 | 138,602 | $2.2M | 10.4% |
| 6 | $16.20 | 138,602 |
| $2.2M |
| 10.4% |
| Total | $16.21 avg | 1,330,318 | $21.6M | 100% |
| Filing → |
| ROIV | SELL | 2026-09-01 | $7.2M | — | Filing → |
| ROIV | SELL | 2026-07-29 | $7.0M | — | Filing → |
| IMVT | SELL | 2026-07-06 | $119K | — | Filing → |